Symbols

CTMX

CytomX Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CTMX

Cytomx Therapeutics, Inc.

A leader in the field of conditionally activated oncology therapeutics

Industry

Pharmaceutical

Established Date

Listing Date

10/08/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cytomx.com

Security Type

Common stock

Office address

151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080

Business

Introduction

CytomX Therapeutics, Inc., was incorporated in Delaware in September 2010 and its operations began in 2008. The Company is a clinical-stage, oncology-focused biopharmaceutical company developing innovative therapies based on its proprietary PROBODY technology platform. The platform enables conditionally activated biologics designed to selectively target tumors, and its state-of-the-art clinical program, Varseta-M, is an antibody-drug conjugate in Phase 1 development for colorectal cancer.

Company Financials

EPS

CTMX has released its 2025 Q4 earnings. EPS was reported at -0.33, versus the expected -0.09, missing expectations. The chart below visualizes how CTMX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CTMX has released its 2025 Q4 earnings report, with revenue of 663.00K, reflecting a YoY change of -98.26%, and net profit of -26.51M, showing a YoY change of -240.44%. The Sankey diagram below clearly presents CTMX's revenue sources and cost distribution.